Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab in Japanese Subjects with Mild to Moderate Alzheimer's Disease
NCT02434718Phase 1Completed
- Sponsor
- Biogen
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aducanumab in Alzheimer's disease (AD) (4 cohorts), sponsored by Biogen. Primary endpoints: Incidence and nature of adverse events (AE) / serious adverse events (SAE), Clinically significant changes in vital signs and 12-lead electrocardiogram (ECG) data and 1 more. Started Jun 2015; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02434718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434718.